Alcohol
Volume 20, Issue 3 , Pages 227-236 , April 2000

Design and structure-activity relationship analysis of ligands of gamma-hydroxybutyric acid receptors

Received 25 May 1998 ,Revised 6 July 1998 ,Accepted 13 July 1998.

References 

  1. Addolorato G, Caputo F, Capristo E, Stefanini GF, Gasbarrini G. Gamma-hydroxybutyric acid (efficacy potential abuse and dependence in the treatment of alcohol addiction). Alcohol. 2000;20:217–222
  2. Allan RD, Johnson GAR. Synthetic analogs for the study of GABA as a neurotransmitter. Med Res Rev. 1983;3:91–118
  3. Arena C, Fung HL, Amherst NU. Absorption of sodium gamma-hydroxybutyric acid and its prodrug gamma-butyrolactone (relationship between in vitro transport and in vivo absorption). J Pharm Sci. 1980;69:356–358
  4. Ariëns, E. J., Beld, A. D., Miranda, J. F. R., & Simonis, A. M. (1979). The pharmacon–receptor–effector concept: A basis for understanding the transmission of information in biological systems. In R. D. O'Brien (Ed.), The receptors, Vol. 1 (pp. 33–91). New York: Plenum Press.
  5. Benavides J, Rumigny JF, Bourguignon JJ, Cash C, Wermuth CG, Mandel P, et al. High affinity binding site for γ-hydroxybutyric acid in rat brain. Life Sci. 1982;30:53–961
  6. Bernasconi R, Lauber J, Marescaux C, Vergnes M, Martin P, Rubio V, et al. Experimental absence seizures (potential role of gamma-hydroxybutyric acid and GABAB receptors). J Neural Transm. 1992;35:155–177
  7. Breckenridge RJ, Nicholson SH, Nicol AJ, Suckling CJ, Leigh B, Iversen L. Inhibition of [3H]GABA binding to postsynaptic receptors in human cerebellar synaptic membranes by carboxyl and amino derivatives of GABA. J Neurochem. 1981;37:837–844
  8. Cignarella G, Barlocco D, Pocar D, Clerici F, Curzu MM, Gessa GL, et al. Synthesis and pharmacological evaluation of a new series of substituted benzoyl-γ-butyrolactone derivatives. Eur J Med Chem. 1995;30:721–726
  9. Colombo G, Mosca E, Gessa GL, Fadda F. Suppression of ethanol intake in ethanol-preferring rats by 1,4-butanediol. Alcohol. 1990;7:503–505
  10. Colombo G, Agabio R, Bourguignon JJ, Fadda F, Lobina C, Maitre M, et al. Blockade of the discriminative stimulus effects of γ-hydroxybutyric acid (GHB) by the GHB receptor antagonist NCS-382. Physiol Behav. 1995;58:587–590a
  11. Colombo G, Agabio R, Lobina C, Reali R, Fadda F, Gessa GL. Symmetrical generalization between the discriminative stimulus effects of gamma-hydroxybutyric acid and ethanol. Physiol Behav. 1995;57:105–111b
  12. Craig PN. Guidelines for drug and analog design. In:  Wolff ME editors. The Basis of Medicinal Chemistry, 4th ed., part 1. New York: Wiley-Interscience; 1980;p. 331–348
  13. Depaulis A, Bourguignon JJ, Marescaux C, Vergnes M, Schmitt M, Micheletti G, et al. Effects of gamma-hydroxybutyrate and gamma-butyrolactone derivatives on spontaneous generalized non-convulsive seizures in the rat. Neuropharmacology. 1988;27:683–689
  14. Doberty JC, Snead OC, Roth RH. A sensitive method for quantitation of gamma-hydroxybutyric acid and gammabutyrolactone in brain by electron capture gas chromatography. Anal Biochem. 1975;69:268–277a
  15. Doberty JC, Hattox SE, Snead OC, Roth RH. Metabolism of [1-14C]gamma-hydroxybutyric acid by rat brain after intraventricular injection. Biochem Pharmacol. 1975;24:469–474b
  16. Fishbein WN, Bessmann SP. Purification and properties of an enzyme in human blood and rat liver microsomes catalyzing the formation of hydrolysis of gamma-lactones. J Biol Chem. 1966;241:4842–4847
  17. Flunk WE, Covey DF, Ferrendelli JA. Anticonvulsant properties of α-, γ-, and α,γ-substituted γ-butyrolactones. Mol Pharmacol. 1982;22:438–443a
  18. Flunk WE, Covey DF, Ferrendelli JA. Comparison of epileptogenic properties of unsubstituted and β-alkyl-substituted gamma-butyrolactones. Mol Pharmacol. 1982;22:431–437b
  19. Galli A, Zilletti L, Scotton M, Adembri G, Giotti A. A study on structural requirements of GABA-analogues for interaction with GABA receptor sites in rat brain. Pharm Res Commun. 1980;12:267–272
  20. Gallimberti L, Spella M, Soncini CA, Gessa GL. Gamma-hydroxybutyric acid in the treatment of alcohol and heroin addiction. Alcohol. 2000;20:257–262
  21. Gessa GL, Agabio R, Carai MAM, Lobina C, Pani M, Reali R, et al. Mechanism of the antialcohol effect of gamma-hydroxybutyric acid. Alcohol. 2000;20:271–276
  22. Godbout R, Pivik RK. EEG and behavioral effects of gamma-hydroxybutyrate in the rabbit. Life Sci. 1982;31:739–748
  23. Godbout R, Jelenic P, Labrie C, Schmitt M, Bourguignon JJ. Effect of gamma-hydroxybutyrate and its antagonist NCS-382 on spontaneous cell firing in the prefrontal cortex of the rat. Brain Res. 1995;673:157–160
  24. Hechler V, Schmitt M, Bourguignon JJ, Maitre M. Trans- γ-hydroxycrotonic acid binding sites in brain (evidence for a subpopulation of γ-hydroxybutyrate sites). Neurosci Lett. 1990;110:204–209
  25. Hechler V, Peter P, Gobaille S, Bourguignon JJ, Schmitt M, Ehrhardt JD, et al. γ-Hydroxybutyrate ligands possess antidopaminergic and neuroleptic-like activities. J Pharmacol Exp Ther. 1993;264:1406–1414
  26. Johnston, G. A. R., Allan, R. D., Kennedy, S. M. E., & Twitchin, B. (1979). Systematic study of GABA analogues of restricted conformation. In Krogsgaard-Larsen, Scheel-Kruger, & Kofod (Eds.), GABA-Neurotransmitters (pp. 149–164). Copenhagen: Alfred Benzon Foundation, Munksgaard.
  27. Krogsgaard-Larsen P, Johnston GAR, Curtis DR, Gama CJA, Mcculloch RM. Structure and biological activity of a series of conformationally restricted analogues of GABA. J Neurochem. 1975;25:803–809
  28. Laborit H. Sodium 4-hydroxybutyrate. Int J Neuropharmacol. 1964;3:433–452
  29. Levine JA, Ferrendelli JA, Coveyd F. Convulsant and anti-convulsant gammabutyrolactones bind at the picrotoxinin/t-butylbicyclophosphorothionate (TBPS) receptor. Biochem Pharmacol. 1985;34:4187–4190
  30. Maitre M. The gamma-hydroxybutyrate signalling system in brain (organization and functional implications). Prog Neurobiol. 1997;51:337–361
  31. Maitre M, Hechler V, Vayer P, Gobaille S, Cash CD, Schmitt M, et al. A specific γ-hydroxybutyrate receptor ligand possesses both antagonistic and anticonvulsant properties. J Pharmacol Exp Ther. 1990;255:657–663
  32. Malawski B, Kulig K, Ciechanowicz-Rutkowska M. Structure-activity relationship studies of new N-substituted amides of α-piperazine- γ-hydroxybutyric acid as active anticonvulsants. Arch Pharm Pharm Med Chem. 1997;330:91–99
  33. Maxwell R, Roth RJ. Conversion of 1,4-butanediol to gamma-hydroxybutyric acid in rat brain and in peripheral tissue. Biochem Pharmacol. 1971;21:1521–1533
  34. Melikian A, Schlewer G, Chambon JP, Wermuth CG. Condensation of muscimol or thiomuscimol with aminopyridazines yields GABAA antagonists. J Med Chem. 1992;35:4092–4097
  35. Moncini, M., Masini, E., Gambassi, F., & Mannaioni, P. F. (in press). The journey of gamma-hydroxybutyric from the laboratory to the alcoholic patient. Alcohol.
  36. Roth RH, Giarman NJ. Gamma-butyrolactone and gamma-hydroxybutyric acid I (distribution and metabolism). Biochem Pharmacol. 1966;15:1333–1348b
  37. Roth RH, Giarman NJ. Evidence that central nervous system depression by 1,4-butanediol is mediated through a metabolite, gamma-hydroxybutyrate. Biochem Pharmacol. 1968;17:735–739
  38. Roth RH, Suhr Y. Mechanism of the gamma-hydroxybutyrate-induced increase in brain dopamine and its relationship to “sleep.”. Biochem Pharmacol. 1970;19:3001–3012
  39. Roth RH, Levy R, Giarman NJ. Dependence of rat serum lactonase upon calcium. Biochem Pharmacol. 1966;16:596–598a
  40. Schmidt C, Gobaille S, Hechler V, Schmitt M, Bourguignon JJ, Maitre M. Anti-sedative and anti-cataleptic properties of NCS-382, a γ-hydroxybutyrate receptor antagonist. Eur J Pharmacol. 1991;203:393–397
  41. Schmitt M, Bourguignon JJ, Wermuth CG, Schott D, Rousseau B, Beaucourt JP. Synthesis of [3H]-labelled trans 4-hydroxycrotonic acid (T-HCA) (an endogenous substance interfering with 4-hydroxybutyrate (GHB)). J Labelled Compd Radiopharm. 1988;27:23–33
  42. Snead OC. Gamma-hydroxybutyrate. Life Sci. 1977;20:1935–1944
  43. Snead OC. An investigation of the relationship between the dopaminergic and electroencephalographic effects of gamma-butyrolactone. Neuropharmacology. 1982;21:539–543
  44. Snead OC, Furner R, Liu CC. In vivo conversion of gamma-aminobutytric acid and 1,4-butanediol to gamma-hydroxybutyric acid in rat brain (studies using stable isotopes). Biochem Pharmacol. 1989;38:4375–4380
  45. Sprince H, Josephs JA, Wilpizeski CR. Neuropharmacological effects of 1,4-butanediol and related congeners compared with those of gamma-hydroxybutyrate and gamma-butyrolactone. Life Sci. 1966;5:2041–2052
  46. Vayer P, Dessort D, Bourguignon JJ, Wermuth CG, Mandel P, Maitre M. Natural occurrence of trans-gamma hydroxycrotonic acid in rat brain. Biochem Pharmacol. 1985;34:2401–2404
  47. Vayer P, Mandel P, Maitre M. Gamma-hydroxybutyrate, a possible neurotransmitter. Life Sci. 1987;41:1547–1557
  48. Wermuth CG, Biziere K. Pyridazinyl-GABA derivatives (a new class of synthetic GABAA antagonists). Trends Pharmacol Sci. 1986;7:421–424

PII: S0741-8329(99)00086-5

Alcohol
Volume 20, Issue 3 , Pages 227-236 , April 2000

Article Tools

* Image Usage & Resolution